Melanoma following treatment with alemtuzumab for multiple sclerosis.
Pace
A A
AA
Zajicek
J P
JP
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009508:Nevus, Pigmented / Q000473:pathology*; D012878:Skin Neoplasms / Q000209:etiology* / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab